Showing results (11-20 of 84) with videos related to
Sort By:
Pageof 9
Pharmacoeconomics|May 3, 2023
How Much Better is Faster? Value Adjustments for Health-Improvement SequencesF Reed Johnson, Juan Marcos Gonzalez, John J Sheehan, et al.Patient Preference and Adherence|August 20, 2016
Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptinAmanda M Farr, John J Sheehan, Brian M Davis, et al.Diabetes, Obesity & Metabolism|October 28, 2017
Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA: An analysis of the NHANES surveys from 1999 to 2014Herve Caspard, Serge Jabbour, Niklas Hammar, et al.Plos One|August 9, 2019
An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depressionBingcao Wu, Qian Cai, John J Sheehan, et al.Current Medical Research and Opinion|September 22, 2019
Descriptive analysis of the economic burden of treatment resistance in a major depressive episodeQian Cai, John J Sheehan, Bingcao Wu, et al.Current Medical Research and Opinion|January 28, 2020
Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depressionDominic Pilon, Holly Szukis, David Singer, et al.Journal of Affective Disorders|March 23, 2013
Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depressionIbrahim Turkoz, Dong-Jing Fu, Cynthia A Bossie, et al.Pharmacoeconomics|October 4, 2024
How Much Better is Faster? Empirical Tests of QALY Assumptions in Health-Outcome SequencesF Reed Johnson, John J Sheehan, Semra Ozdemir, et al.Plos One|June 13, 2018
Assessment of the relationship between diabetes treatment intensification and quality measure performance using electronic medical recordsRenée J G Arnold, Shuo Yang, Edward J Gold, et al.Current Drug Safety|June 10, 2014
Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and medicaid insured patients newly initiating atypical antipsychoticsLeslie Citrome, Stephen Johnston, Anagha Nadkarni, et al.Pageof 9